Using blood treosulfan concentrations to reduce toxicity and improve outcome in children undergoing stem cell transplantation.

Trial Profile

Using blood treosulfan concentrations to reduce toxicity and improve outcome in children undergoing stem cell transplantation.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Treosulfan (Primary)
  • Indications Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Malignant melanoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 Planned End Date changed from 16 Oct 2018 to 16 Oct 2023.
    • 27 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top